MoonLake Immunotherapeutics.
MLTX.US | Research and experimental development on natural sciences and engineering
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-mediated diseases. Their primary focus is on developing Sonelokimab, a Nanobody® targeting IL-17A/F, for the treatment of inflammatory diseases, including hidradenitis suppurati...Show More
Better Health for All
0
No relevant data for MoonLake Immunotherapeutics (MLTX.US) was found in the provided articles to assess any of the 'Better Health for All' KPIs. Articles
1
and
2
pertain to a different company, Calian Group Ltd.
3
4
Article
5
, from MoonLake's website, explicitly states a lack of quantitative data or information relevant to assessing the company's impact on health outcomes.
6
Articles
7
,
8
, and
9
failed to extract content.
10
11
12
Fair Money & Economic Opportunity
0
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on research and development of therapies. The company does not offer lending, deposit, or other financial services to consumers.
1
Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to its business model, as per the rubric's definitions for a score of 0.
Fair Pay & Worker Respect
0
No evidence available to assess MoonLake Immunotherapeutics on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on research and development, and does not currently manufacture or distribute approved pharmaceutical products. As such, the company does not procure or trade physical commodities, nor does it have a supplier base or supply chain tiers that would typically require fair-trade certifications, welfare or sourcing audits, or mapping for provenance. Consequently, there is no exposure to upstream labor practices or high-risk materials as defined by the rubric. The provided article contains no data relevant to fair trade and ethical sourcing practices.
1
Honest & Fair Business
-40
MoonLake Immunotherapeutics updated its Code of Conduct and Ethics on December 13, 2023, to clarify procedures for communicating reports to the Audit Committee and update employee contact information for reporting concerns.
1
Additionally, a March 2025 loan agreement includes provisions for the company's compliance with anti-corruption laws, such as the FCPA and UK Bribery Act.
2
Kind to Animals
-50
The company conducts preclinical laboratory tests and animal studies, including in vivo studies, in accordance with FDA’s current Good Laboratory Practices (GLP) regulation.
1
In vitro studies are also mentioned.
2
The use of llamas in medical research is regulated.
3
However, no specific company policy restricting animal testing beyond legal mandates is provided, nor is the extent to which non-animal methods are employed for product safety and efficacy quantified.
4
No War, No Weapons
0
MoonLake Immunotherapeutics (MLTX.US) has no involvement in military contracting, controversial weapons, or small arms.
1
The company's core business is focused on developing therapies for immune-mediated diseases, and it does not currently manufacture or distribute approved pharmaceutical products.
2
There is no evidence of dual-use technology, sales to embargoed regimes, exports, or involvement in intelligence or surveillance activities.
3
The company also has no reported exposure to conflict minerals or procurement from conflict-affected areas.
4
Planet-Friendly Business
0
No specific data regarding MoonLake Immunotherapeutics' planet-friendly business practices, environmental performance, or climate-related initiatives could be found in the provided articles. was a 'page not found' error,
1
and discussed general federal recommendations for sustainable purchasing without mentioning MLTX.US.
2
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to assess MoonLake Immunotherapeutics against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles primarily focus on the company's clinical trial progress, financial performance, corporate governance, and general patient support initiatives, rather than specific engagements with indigenous or local community groups, cultural preservation efforts, or related impact assessments. Information about disease-specific support groups does not align with the value's focus on cultural heritage or indigenous autonomy.
Safe & Smart Tech
0
The company's privacy policy, last updated February 19, 2025, states compliance with the Swiss Federal Act on Data Protection (FADP), EU GDPR, and UK GDPR.
1
It also outlines user rights regarding data access, rectification, restriction, deletion, and portability.
2
The company is subject to extensive regulations by authorities such as the FDA and EMA, and must comply with healthcare regulatory laws including HIPAA, CCPA, and CPRA.
3
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding MoonLake Immunotherapeutics' performance on any of the Zero Waste & Sustainable Products KPIs. The company is a clinical-stage biopharmaceutical company focused on research and development, partnering with third-party contract manufacturing organizations (CMOs) for drug substance and finished drug product.
1
While articles mention that these manufacturers are subject to regulatory compliance (e.g., cGMPs),
2
there is no evidence of MLTX.US's own waste management performance, product recyclability, packaging sustainability, or any related initiatives or targets.